Ashford Capital Management Inc. Trims Holdings in Progyny, Inc. (NASDAQ:PGNY)

Ashford Capital Management Inc. lessened its holdings in Progyny, Inc. (NASDAQ:PGNY) by 40.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 229,090 shares of the company’s stock after selling 158,134 shares during the quarter. Ashford Capital Management Inc. owned about 0.27% of Progyny worth $3,840,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of PGNY. State Street Corp raised its holdings in shares of Progyny by 4.5% during the third quarter. State Street Corp now owns 3,113,654 shares of the company’s stock worth $52,185,000 after purchasing an additional 134,861 shares during the last quarter. International Assets Investment Management LLC increased its holdings in shares of Progyny by 1,576.0% during the 3rd quarter. International Assets Investment Management LLC now owns 2,565,118 shares of the company’s stock valued at $42,991,000 after purchasing an additional 2,412,068 shares in the last quarter. Pacer Advisors Inc. lifted its stake in shares of Progyny by 12,579.4% in the 3rd quarter. Pacer Advisors Inc. now owns 2,492,642 shares of the company’s stock valued at $41,777,000 after purchasing an additional 2,472,983 shares during the period. Invenomic Capital Management LP purchased a new stake in Progyny during the third quarter worth $29,509,000. Finally, Farallon Capital Management LLC grew its position in Progyny by 120.8% during the second quarter. Farallon Capital Management LLC now owns 1,308,500 shares of the company’s stock valued at $37,436,000 after buying an additional 715,900 shares during the period. Institutional investors and hedge funds own 94.93% of the company’s stock.

Progyny Trading Up 7.3 %

Progyny stock opened at $15.84 on Tuesday. The stock has a market cap of $1.35 billion, a P/E ratio of 27.31, a PEG ratio of 1.66 and a beta of 1.35. The company has a 50-day moving average price of $15.61 and a 200 day moving average price of $21.63. Progyny, Inc. has a 12-month low of $13.39 and a 12-month high of $42.08.

Progyny (NASDAQ:PGNY) last released its quarterly earnings results on Tuesday, November 12th. The company reported $0.11 EPS for the quarter, missing the consensus estimate of $0.37 by ($0.26). The firm had revenue of $286.63 million for the quarter, compared to analysts’ expectations of $296.85 million. Progyny had a net margin of 5.03% and a return on equity of 11.36%. The firm’s quarterly revenue was up 2.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.16 EPS. As a group, analysts forecast that Progyny, Inc. will post 0.59 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently issued reports on PGNY. Cantor Fitzgerald reissued an “overweight” rating and set a $25.00 target price on shares of Progyny in a research note on Tuesday, October 1st. Canaccord Genuity Group reduced their price objective on Progyny from $18.00 to $17.00 and set a “hold” rating for the company in a research note on Wednesday, November 13th. Barclays lowered their target price on shares of Progyny from $30.00 to $17.00 and set an “overweight” rating on the stock in a research note on Thursday, November 14th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $17.00 target price (down previously from $22.00) on shares of Progyny in a report on Monday, December 2nd. Finally, Truist Financial reissued a “hold” rating and issued a $19.00 price target (down from $26.00) on shares of Progyny in a research note on Wednesday, November 13th. Nine investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $25.00.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.